Brainsway (NASDAQ: NASDAQ:BWAY) has maintained its Buy rating and a $16.00 price target from H.C. Wainwright.
The firm's positive stance comes after Brainsway's announcement of expanding its Deep Transcranial Magnetic Stimulation (Deep TMS) platform across the East Coast with a significant new order.
The company disclosed on September 16 that it had received an order for 14 new systems from a large and growing enterprise network, indicating a continued preference for Brainsway's technology among mental health providers.
This latest development is part of a trend of recent multisystem orders that Brainsway has secured, signaling a solidifying market presence. As of June 30, 2024, the company reported having an installed base of 1,215 Deep TMS systems.
The expansion reflects the company's ongoing efforts to solidify its footprint in the mental health treatment space.
H.C. Wainwright's analyst highlighted the company's financial prospects, maintaining a forecast of $40 million in top-line revenue for the year 2024.
The firm's expectation for 2025 remains optimistic, with a revenue forecast of $44.3 million. The analyst's reiterated Buy rating and price target reflect confidence in Brainsway's growth trajectory and financial performance.
In other recent news, BrainsWay Ltd. has reported substantial financial growth with a 37% year-over-year revenue increase in Q1 2024, marking the second consecutive quarter of positive net income.
The company also shipped 57 Deep Transcranial Magnetic Stimulation (Deep TMS) systems during this period, further solidifying its financial strength. BrainsWay's revenue guidance for 2024 is projected to be between $37 million and $40 million, indicating a growth of 16% to 26% from the previous year's revenue.
In addition to financial growth, BrainsWay has secured reimbursement for PTSD treatment in Israel, a significant development for eligible patients at Israeli public hospitals. This follows a study showing substantial reduction in PTSD symptoms with Deep TMS treatment. The company is also actively extending reimbursement coverage to more medical centers and possibly private clinics.
BrainsWay has appointed Dr. Richard A. Bermudes as its new Chief Medical Officer, bringing over two decades of experience in brain stimulation therapies to the company. The company has also expanded into the Canadian healthcare sector through an exclusive distribution agreement, with plans to deliver a minimum of 11 Deep TMS systems in 2024.
Lastly, the FDA has expanded the age range for BrainsWay's Deep TMS system, now allowing it to be administered to patients aged 22 to 86 with major depressive disorder.
InvestingPro Insights
Brainsway's recent order for new Deep TMS systems underscores the company's growth potential, a sentiment echoed by H.C. Wainwright's maintained Buy rating and optimistic revenue forecasts. Complementing this perspective, InvestingPro data indicates a strong financial position for Brainsway (NASDAQ:BWAY), with a significant 42% revenue growth over the last twelve months as of Q2 2024 and a robust gross profit margin of 74.82%. Moreover, the company's market capitalization stands at $138.88 million, and despite a high P/E ratio of 232.78, the company has shown a powerful performance with a one-year price total return of 86.18%.
Two noteworthy InvestingPro Tips for Brainsway include the company holding more cash than debt on its balance sheet, which suggests a sound financial structure, and the fact that liquid assets exceed short-term obligations, further indicating financial stability. These insights are particularly relevant to investors considering Brainsway's financial health amidst its expansion efforts. For those seeking additional insights, there are 13 more InvestingPro Tips available, which can provide a deeper analysis of Brainsway's financial metrics and market performance.
Overall, the InvestingPro data and tips offer a comprehensive view of Brainsway's financial health and market potential, complementing the article's focus on the company's strategic growth and the positive outlook from industry analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.